SIGA Technologies Inc. - Q2 2025 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2025. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company primarily focused on the sale of its lead product, TPOXX® (tecovirimat), in oral and intravenous (IV) formulations. The company's revenue is derived mainly from contracts with the U.S. Government (specifically the Strategic National Stockpile via BARDA) and international governments. The company operates as an accelerated filer with no debt obligations reported in the balance sheet.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $81.12 million | $21.81 million | $88.16 million | $47.24 million |
| Net Income | $35.48 million | $1.83 million | $35.07 million | $12.11 million |
| Diluted EPS | $0.49 | $0.03 | $0.49 | $0.17 |
| Operating Cash Flow (YTD) | $70.15 million (2025) vs. ($0.16 million) (2024) | |||
| Cash & Equivalents (End of Period) | $182.46 million | |||
| Total Liabilities | $26.02 million | |||
| Effective Tax Rate (YTD) | 24.9% |
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 272% year-over-year for the quarter and 87% year-over-year for the six months. This was driven by a significant increase in product sales to the U.S. Government under the 19C BARDA contract, specifically $53.3 million in oral TPOXX® and $25.8 million in IV TPOXX® sales in Q2 2025.
- Profitability: Net income jumped from $1.83 million in Q2 2024 to $35.48 million in Q2 2025. Operating income rose from $1.08 million to $45.68 million.
- Cost Structure: Cost of sales increased to $25.55 million (Q2 2025) from $12.31 million (Q2 2024), reflecting higher manufacturing and delivery volumes. This included a $0.9 million inventory write-off in Q2 2025.
- Dividend Payment: The company paid a special cash dividend of approximately $42.9 million in the first half of 2025 ($0.60 per share), compared to $42.7 million in the same period in 2024.
- Contract Modifications: The 19C BARDA contract was amended in 2025 to increase total payments by $27.5 million ($14.3 million for manufacturing support and $13.2 million for pediatric formulation development).
Outlook, Risks, and Management Commentary
- Regulatory Risks (Mpox): The European Medicines Agency (EMA) initiated a referral procedure for Tecovirimat-SIGA following questions regarding its effectiveness in treating mpox, based on results from the PALM007 and STOMP clinical trials which did not meet primary endpoints for lesion resolution. The EMA will review data to determine if the marketing authorization should be maintained, modified, suspended, or withdrawn. A similar reassessment is ongoing with the UK's MHRA.
- Future Pipeline: The company is targeting a Supplemental New Drug Application (NDA) submission to the FDA in 2026 for a smallpox post-exposure prophylaxis (PEP) indication.
- Contractual Obligations: As of June 30, 2025, the company has approximately $62.5 million in active contractual performance obligations. The 19C BARDA contract contemplates up to $630 million in total payments, with $545.2 million related to exercised options.
- Liquidity: Management believes current cash resources ($182.5 million) are sufficient to meet requirements for at least the next 12 months. There are no long-term debt obligations.
- Tax Law Changes: The company is analyzing the impact of the "One Big Beautiful Bill Act" signed into law on July 4, 2025, but does not currently expect a material impact on its effective tax rate.
Investor Verification Checklist
- Verify the status of the EMA referral procedure regarding Tecovirimat-SIGA's mpox indication and potential impact on international sales.
- Confirm the timeline and success probability of the FDA Supplemental NDA for smallpox PEP targeted for 2026.
- Monitor the exercise of unexercised options under the 19C BARDA contract, which total approximately $5.6 million.
- Review the company's strategy for international sales following the amendment of the International Promotion Agreement with Meridian Medical Technologies, LLC.
- Assess the impact of potential tariff changes on the cost of raw materials for IV TPOXX® manufacturing.